Solerte S B, Fioravanti M, Patti A L, Schifino N, Zanoletti M G, Inglese V, Ferrari E
Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia, Italy.
Acta Diabetol Lat. 1987 Jul-Sep;24(3):229-39. doi: 10.1007/BF02732042.
A specific hemorheologic treatment might reduce urinary protein excretion and the decline in kidney function in diabetic patients with overt clinical nephropathy. Twenty-one insulin dependent (type I) diabetic patients were randomized and assigned to a treatment with conventional antihypertensive therapy (protocol I) or with pentoxifylline (Trental 400) (protocol II). A marked improvement of blood rheology pattern, together with a reduction of urinary albumin excretion rate and total urinary protein excretion rate, was demonstrated throughout a 1-year follow-up study with pentoxifylline. Furthermore a decrease of systolic and diastolic blood pressure levels was found during the treatment. The modification of these parameters was followed by a significant increase of creatinine clearance in each of the patients studied. The results obtained during pentoxifylline therapy were comparable to those obtained in patients treated with conventional antihypertensive drugs. Pentoxifylline may therefore be used in the treatment of advanced nephropathy in diabetic patients.
一种特定的血液流变学治疗方法可能会减少显性临床肾病糖尿病患者的尿蛋白排泄及肾功能衰退。21例胰岛素依赖型(I型)糖尿病患者被随机分组,分别接受传统抗高血压治疗(方案I)或己酮可可碱(400mg 特伦他林)治疗(方案II)。在一项为期1年的己酮可可碱随访研究中,血液流变学模式显著改善,同时尿白蛋白排泄率和总尿蛋白排泄率降低。此外,治疗期间收缩压和舒张压水平下降。这些参数的改变之后,每个研究患者的肌酐清除率显著增加。己酮可可碱治疗期间获得的结果与接受传统抗高血压药物治疗的患者所获得的结果相当。因此,己酮可可碱可用于治疗糖尿病患者的晚期肾病。